Vesicular monoamine transporter 2

From Wikipedia, the free encyclopedia
  (Redirected from VMAT2)
Jump to: navigation, search
SLC18A2
Identifiers
Aliases SLC18A2, SVAT, SVMT, VAT2, VMAT2, solute carrier family 18 member A2, Vesicular monoamine transporter 2
External IDs OMIM: 193001 MGI: 106677 HomoloGene: 2298 GeneCards: SLC18A2
Gene location (Human)
Chromosome 10 (human)
Chr. Chromosome 10 (human)[1]
Chromosome 10 (human)
Genomic location for SLC18A2
Genomic location for SLC18A2
Band No data available Start 117,241,093 bp[1]
End 117,279,430 bp[1]
Orthologs
Species Human Mouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_003054

NM_172523

RefSeq (protein)

NP_003045

NP_766111

Location (UCSC) Chr 10: 117.24 – 117.28 Mb Chr 10: 59.26 – 59.3 Mb
PubMed search [3] [4]
Wikidata
View/Edit Human View/Edit Mouse
Distribution of VMAT2 in the human brain.

The vesicular monoamine transporter 2 (VMAT2) also known as solute carrier family 18 member 2 (SLC18A2) is a protein that in humans is encoded by the SLC18A2 gene.[5] VMAT2 is an integral membrane protein that transports monoamines—particularly neurotransmitters such as dopamine, norepinephrine, serotonin, and histamine—from cellular cytosol into synaptic vesicles.[6] In nigrostriatal pathway and mesolimbic pathway dopamine-releasing neurons, VMAT2 function is also necessary for the vesicular release of the neurotransmitter GABA.[7]

Binding sites and ligands[edit]

VMAT2 is believed to possess at least two distinct binding sites, which are characterized by tetrabenazine (TBZ) and reserpine binding to the transporter.[8] Amphetamine (TBZ site) and methamphetamine (reserpine site) bind at distinct sites on VMAT2 to inhibit its function.[8] VMAT2 inhibitors like tetrabenazine and reserpine reduce the concentration of monoamine neurotransmitters in the synaptic cleft by inhibiting uptake through VMAT2; the inhibition of VMAT2 uptake by these drugs prevents the storage of neurotransmitters in synaptic vesicles and reduces the quantity of neurotransmitters that are released through exocytosis. Although many substituted amphetamines induce the release of neurotransmitters from vesicles through VMAT2 while inhibiting uptake through VMAT2, they facilitate the release of monoamine neurotransmitters into the synaptic cleft by simultaneously reversing the direction of transport through the primary plasma membrane transport proteins for monoamines (i.e., the dopamine transporter, norepinephrine transporter, and serotonin transporter) in monoamine neurons.[medical citation needed] Other VMAT2 inhibitors such as GZ-793A inhibit the reinforcing effects of methamphetamine, but without producing stimulant or reinforcing effects themselves.[9]

Inhibition[edit]

VMAT2 is essential for enabling the release of neurotransmitters from the axon terminals of monoamine neurons into the synaptic cleft. If VMAT2 function is inhibited or compromised, monoamine neurotransmitters such as dopamine cannot be released into the synapse via typical release mechanisms (i.e., exocytosis resulting from action potentials).

Cocaine users display a marked reduction in VMAT2 immunoreactivity. Sufferers of cocaine-induced mood disorders displayed a significant loss of VMAT2 immunoreactivity; this might reflect damage to dopamine axon terminals in the striatum. These neuronal changes could play a role in causing disordered mood and motivational processes in more severely addicted users.[10]

In popular culture[edit]

Geneticist Dean Hamer has suggested that a particular allele of the VMAT2 gene correlates with spirituality using data from a smoking survey, which included questions intended to measure "self-transcendence". Hamer performed the spirituality study on the side, independently of the National Cancer Institute smoking study. His findings were published in the mass-market book The God Gene: How Faith Is Hard-Wired Into Our Genes.[11][12] Hamer himself notes that VMAT2 plays at most a minor role in influencing spirituality.[13] Furthermore, Hamer's claim that the VMAT2 gene contributes to spirituality is controversial.[13] Hamer's study has not been published in a peer reviewed journal and a reanalysis of the correlation demonstrates that it is not statistically significant.[13][14]

References[edit]

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000165646 - Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000025094 - Ensembl, May 2017
  3. ^ "Human PubMed Reference:". 
  4. ^ "Mouse PubMed Reference:". 
  5. ^ Surratt CK, Persico AM, Yang XD, Edgar SR, Bird GS, Hawkins AL, Griffin CA, Li X, Jabs EW, Uhl GR (March 1993). "A human synaptic vesicle monoamine transporter cDNA predicts posttranslational modifications, reveals chromosome 10 gene localization and identifies TaqI RFLPs". FEBS Lett. 318 (3): 325–30. PMID 8095030. doi:10.1016/0014-5793(93)80539-7. 
  6. ^ Eiden LE, Schäfer MK, Weihe E, Schütz B (February 2004). "The vesicular amine transporter family (SLC18): amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine". Pflugers Arch. 447 (5): 636–40. PMID 12827358. doi:10.1007/s00424-003-1100-5. 
  7. ^ Tritsch NX, Ding JB, Sabatini BL (2012). "Dopaminergic neurons inhibit striatal output through non-canonical release of GABA". Nature. 490 (7419): 262–6. PMC 3944587Freely accessible. PMID 23034651. doi:10.1038/nature11466. 
  8. ^ a b Sulzer D, Sonders MS, Poulsen NW, Galli A (April 2005). "Mechanisms of neurotransmitter release by amphetamines: a review". Prog. Neurobiol. 75 (6): 406–33. PMID 15955613. doi:10.1016/j.pneurobio.2005.04.003. They also demonstrated competition for binding between METH and reserpine, suggesting they might bind to the same site on VMAT. George Uhl’s laboratory similarly reported that AMPH displaced the VMAT2 blocker tetrabenazine (Gonzalez et al., 1994). It should be noted that tetrabenazine and reserpine are thought to bind to different sites on VMAT (Schuldiner et al., 1993a) 
  9. ^ Alvers KM, Beckmann JS, Zheng G, Crooks PA, Dwoskin LP, Bardo MT (2012). "The effect of VMAT2 inhibitor GZ-793A on the reinstatement of methamphetamine-seeking in rats". Psychopharmacology (Berl.). 224 (2): 255–62. PMID 22638813. doi:10.1007/s00213-012-2748-3. 
  10. ^ Little KY, Krolewski DM, Zhang L, Cassin BJ (January 2003). "Loss of striatal vesicular monoamine transporter protein (VMAT2) in human cocaine users". Am J Psychiatry. 160 (1): 47–55. PMID 12505801. doi:10.1176/appi.ajp.160.1.47. 
  11. ^ Hamer DH (2004). The God gene: how faith is hardwired into our genes. Garden City, N.Y: Doubleday. ISBN 0-385-50058-0. 
  12. ^ Kluger J, Chu J, Liston B, Sieger M, Williams D (2004-10-25). "Is God in our genes?". TIME. Time Inc. Retrieved 2007-04-08. 
  13. ^ a b c Silveira LA (2008). "Experimenting with spirituality: analyzing The God Gene in a nonmajors laboratory course". CBE Life Sciences Education. 7 (1): 132–45. PMC 2262126Freely accessible. PMID 18316816. doi:10.1187/cbe.07-05-0029. 
  14. ^ Zimmer C (October 2004). "Faith-Boosting Genes: A search for the genetic basis of spirituality". Scientific American. 

Further reading[edit]

External links[edit]